Stay updated on Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.

Latest updates to the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new version of the clinical study, with significant changes in the study's description and the addition of key collaborators and investigators. The study now emphasizes its focus on evaluating the immune and clinical response to poly-ICLC in combination with anti-PD-1 or anti-PD-L1 therapies.SummaryDifference40%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.